Location: Boston MA, New Haven CT, Hackensack NJ, Philadelphia PA,
Sponsor: Normunity AccelCo, Inc.
Sex: All
Age: 18+
Code: NCT07182149
Phase1, Recruiting
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
for
Non-Small Cell Lung Cancer,
Location: Montreal, Fairfax VA, Durham NC, Toronto,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT05005403
Phase1, Recruiting
Featured
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
for
Non-Squamous Non-Small Cell Lung Cancer
Location: Ottawa, Fairfax VA, Orange City FL, Houston TX,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT07005102
Phase2, Phase3, Recruiting
Featured
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
for
Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer
Location: New York NY, Philadelphia PA, Nashville TN, Chicago IL,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT06858813
Phase1, Recruiting
New
Effects of Infusion Timing on Treatment Response in Solid Tumors